



## Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine

Haiqin Ping<sup>1</sup> · Wenjun Yu<sup>1</sup> · Xiaoming Gong<sup>1</sup> · Xin Tong<sup>1</sup> · Cheyu Lin<sup>1</sup> · Zhaojun Chen<sup>1</sup> · Caiyun Cai<sup>1</sup> · Kai Guo<sup>1</sup> · Hengning Ke<sup>1,2,3</sup>

Received: 15 August 2022 / Accepted: 17 August 2022 / Published online: 27 August 2022  
© Springer Science+Business Media, LLC, part of Springer Nature 2022

**Correction to: Investigational New Drugs**  
<https://doi.org/10.1007/s10637-022-01290-y>

Author information was missing and will be added.

"Haiqin Ping and Wenjun Yu are joint first authors."

The original article has been corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The original article can be found online at <https://doi.org/10.1007/s10637-022-01290-y>.

---

✉ Hengning Ke  
kehengning@znhospital.cn

Haiqin Ping  
1723392486@qq.com

Wenjun Yu  
ywj341022@163.com

Xiaoming Gong  
15172734978@163.com

Xin Tong  
2019203030011@whu.edu.cn

Cheyu Lin  
Alan\_lin@heekis.com

Zhaojun Chen  
czj318mi@163.com

Caiyun Cai  
2020283030080@whu.edu.cn

Kai Guo  
guokai4937@163.com

- <sup>1</sup> Department of Infectious Disease, Zhongnan Hospital of Wuhan University, Hubei AIDS Clinical Training Center, Wuhan, People's Republic of China
- <sup>2</sup> Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, People's Republic of China
- <sup>3</sup> Cancer Research Institute, General Hospital, Ningxia, Medical University, Yinchuan, People's Republic of China